SBIR/STTR Research Award
CYTOMETRY-AIDED DEVELOPMENT OF ANTIMICROBIAL AGENTS
Award amount
$81,525Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HOWARD M. SHAPIRO, MD, P.C.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): There has recently been an alarming
increase in infections due to bacteria resistant to all available antibiotics.
Tetracycline resistance is typically mediated by efflux pumps; tetracycline
derivatives which inhibit them may be used in combination with existing
tetracyclines to treat infections by resistant organisms. Flow cytometric
methods will be developed to facilitate measurement of tetracycline uptake and
efflux in bacteria, and detection of effects of tetracyclines and daptomycin on
membrane potential, pH, and permeability. Another method of potentiating
existing antibiotics is suggested by the finding that bacteria treated with
sublethal doses of some antibiotics become transiently permeable to dyes that
normally do not penetrate the membranes of either bacterial or mammalian cells.
The chemical modifications used to make dyes impermeant can be applied to
various toxic agents; these modified agents should be nontoxic to host cells,
but kill transiently permeabilized bacteria. This hypothesis, which may provide
a novel and general therapeutic approach to bacterial infections, will be
tested using fluorescent nucleic acid binding compounds with known permeant and
impermeant characters; antibiotic-sensitive and -resistant Staphylococcus and
Enterococcus species and Escherichia coli will be examined.
PROPOSED COMMERCIAL APPLICATION:
There is a substantial market in drug companies and research institutions for assays and
related instrumentation which facilitate rapid development of new antimicrobial agents.
Moreover, drugs or combinations which improved treatment of infections due to even
a few antibiotic-resistant bacterial species would capture a significant share of a huge
market for antibacterial agents.
Technology keywords
Not reported